Corticosteroids for the long-term treatment in multiple sclerosis

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2006, Pages

  Ciccone, Alfonso ^a   Beretta, S ^b   Brusaferri, F ^b   Spreafico, C ^b   Protti, A ^b  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; METHYLPREDNISOLONE; PREDNISONE; STEROID;

DISEASE COURSE; DISEASE EXACERBATION; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; LONG TERM CARE; MULTIPLE SCLEROSIS; RELAPSE; REMISSION; REVIEW; RISK; SYMPTOM;

EID: 42749103807     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006264     Document Type: Review

References (23)

1. Barkhof F, Tas MW, Frequin ST, Scheltens P, Hommes OR, Nauta JJ, Valk J. Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. Neuroradiology 1994;36(5):382-387.
2. Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. The New England Journal of Medicine 1993;329(24):1764-1769.
3. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. Journal of Neurology 2000;247:435-442.
4. Compston A, Coles A. Multiple sclerosis. The Lancet 2002;359:1221-1231.
5. de Seze J, Chapelotte M, Delalande S, Ferriby D, Stojkovic T, Vermersch P. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Multiple Sclerosis 2004;10(5):596-597.
6. Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R, Candelise L. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. In: The Cochrane Database of Systematic Reviews, 4, 2000. Oxord: Update Software.
7. Frohman EM, Stüve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Archives of Neurology 2005;62(10):1519-1530.
8. Gasperini C, Pozzilli C, Bastianello S, Koudriavtseva T, Colleluori A, Millefiorini E, Thompson AJ, Horsfield MA, Galgani S, Bozzao L, Fieschi C. The inuence of clinical relapses and steroid therapy on the development of Gd-enhancing lesions: a longitudinal MRI study in relapsing-remitting multiple sclerosis patients. Acta Neurologica Scandinavica 1997;95(4):201- 207.
9. Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. Journal of Neuroimmunology 2001;117:1-8.
10. Goodkin DE, Kinkel RP, Weinstock-Guttman B, VanderBrug-Medendorp S, Secic M, Gogol D, Perryman JE, Uccelli MM, Neilley L. A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998;51(1):239-245.
11. Goodkin DE, Rooney WD, Sloan R, Bacchetti P, Gee L, Vermathen M, Waubant E, Abundo M, Majumdar S, Nelson S, Weiner MW. A serial study of new MS lesions and the white matter from which they arise. Neurology 1998;51(6):1689-1697.
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33(11): 1444-1452.
13. McDonald WI, Halliday AM. Diagnosis and classification of multiple sclerosis. British Medical Bullettin 1977;33(1):4-9.
14. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Annals of Neurology 2001;50(1):121-127.
15. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Annals of Neurology 2005;58(6):840-846.
16. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology 1983;13(3):227-231.
17. Pozzilli C, Marinelli F, Romano S, Bagnato F. Corticosteroids treatment. Journal of Neurological Sciences 2004;223(1):47-51.
18. Rizvi SA, Agius MA. Current approved options for treating patients with multiple sclerosis. Neurology 2004;63(12 Suppl 6):S8-14.
19. Rizvi SA, Bashir K. Other therapy options and future strategies for treating patients with multiple sclerosis. Neurology 2004;63(12 Suppl 6):S47-54.
20. Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Multiple Sclerosis 2005;11:425-432.
21. Smith ME, Stone LA, Albert PS, Frank JA, Martin R, Armstrong M, Maloni H, McFarlin DE, McFarland HF. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Annals of Neurology 1993;33(5):480-489.
22. Stone LA, Albert PS, Smith ME, DeCarli C, Armstrong MR, McFarlin DE, Frank JA, McFarland HF. Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 1995;45(10):1808-1814.
23. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57(7):1239-1247.